The MEK inhibitors currently in use clinically target both MEK1 and MEK2 and when combined with BRAF inhibitors in patients with BRAFV600E‐mutant melanoma prolong progression free survival by an average of 4 months in metastatic disease (Robert et al., 2015a). This evidence concerns the gene MAP2K1 and melanoma.